Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Rating of “Buy” from Analysts

Share on StockTwits

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) has received an average rating of “Buy” from the ten ratings firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $15.00.

Several analysts recently weighed in on AUPH shares. Oppenheimer started coverage on shares of Aurinia Pharmaceuticals in a report on Tuesday, September 10th. They issued an “outperform” rating and a $14.00 target price for the company. Royal Bank of Canada reiterated a “buy” rating and issued a $11.00 target price on shares of Aurinia Pharmaceuticals in a report on Thursday, August 8th. Bloom Burton reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 2nd. ValuEngine downgraded shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Thursday, October 10th. Finally, HC Wainwright set a $25.00 price target on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, November 1st.

Aurinia Pharmaceuticals stock opened at $5.22 on Monday. Aurinia Pharmaceuticals has a fifty-two week low of $3.52 and a fifty-two week high of $7.85. The firm has a 50 day moving average price of $4.95 and a 200 day moving average price of $5.89. The company has a market capitalization of $484.63 million, a PE ratio of -6.87 and a beta of 1.07.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Thursday, November 14th. The biotechnology company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.19) by ($0.02). Aurinia Pharmaceuticals had a negative net margin of 19,483.96% and a negative return on equity of 50.57%. The company had revenue of $0.23 million during the quarter, compared to analyst estimates of $0.05 million. As a group, research analysts predict that Aurinia Pharmaceuticals will post -0.68 earnings per share for the current year.

Several large investors have recently bought and sold shares of AUPH. Swiss National Bank grew its stake in shares of Aurinia Pharmaceuticals by 14.0% in the second quarter. Swiss National Bank now owns 111,800 shares of the biotechnology company’s stock worth $738,000 after acquiring an additional 13,700 shares in the last quarter. Wells Fargo & Company MN grew its stake in shares of Aurinia Pharmaceuticals by 35.5% in the second quarter. Wells Fargo & Company MN now owns 77,993 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 20,432 shares in the last quarter. Toronto Dominion Bank grew its stake in shares of Aurinia Pharmaceuticals by 26.3% in the second quarter. Toronto Dominion Bank now owns 12,355 shares of the biotechnology company’s stock worth $81,000 after acquiring an additional 2,575 shares in the last quarter. BlackRock Inc. grew its stake in shares of Aurinia Pharmaceuticals by 3.1% in the second quarter. BlackRock Inc. now owns 921,425 shares of the biotechnology company’s stock worth $6,063,000 after acquiring an additional 28,129 shares in the last quarter. Finally, Vivo Capital LLC grew its stake in shares of Aurinia Pharmaceuticals by 57.7% in the second quarter. Vivo Capital LLC now owns 1,913,623 shares of the biotechnology company’s stock worth $12,592,000 after acquiring an additional 700,333 shares in the last quarter. Institutional investors and hedge funds own 31.36% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.

Featured Article: Penny Stocks

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.